302 related articles for article (PubMed ID: 38398157)
1. Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response.
Vianello C; Monti E; Leoni I; Galvani G; Giovannini C; Piscaglia F; Stefanelli C; Gramantieri L; Fornari F
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398157
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
Rallis KS; Makrakis D; Ziogas IA; Tsoulfas G
World J Clin Oncol; 2022 Jun; 13(6):448-472. PubMed ID: 35949435
[TBL] [Abstract][Full Text] [Related]
5. The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma.
Wang M; Yu F; Chen X; Li P; Wang K
Mol Ther Nucleic Acids; 2020 Sep; 21():13-27. PubMed ID: 32505000
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome.
Afra F; Mahboobipour AA; Salehi Farid A; Ala M
Biomed Pharmacother; 2023 Sep; 165():115104. PubMed ID: 37393866
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies for advanced hepatocellular carcinoma.
Sun LY; Zhang KJ; Xie YM; Liu JW; Xiao ZQ
Front Pharmacol; 2023; 14():1138493. PubMed ID: 37025485
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.
Xiao Z; Shen J; Zhang L; Li M; Hu W; Cho C
Oncol Lett; 2018 Mar; 15(3):3395-3402. PubMed ID: 29467864
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
Li X; Ding X; Li W; Chen J
Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
[TBL] [Abstract][Full Text] [Related]
10. The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things.
Fang Y; Zhang X; Huang H; Zeng Z
J Transl Med; 2023 Jun; 21(1):369. PubMed ID: 37286982
[TBL] [Abstract][Full Text] [Related]
11. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
13. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
14. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis.
Li Z; Xu Y; Qu W; Liu P; Zhu Y; Li H; Guo Y; Liu X
Oncol Lett; 2023 Dec; 26(6):534. PubMed ID: 38020293
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
19. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
20. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
